Recent clinical trials from 2025‑2026 are turning the old belief that atrophic gastritis (AG) is irreversible on its head. Researchers found that several existing medicines, when used in new ways, can actually improve the stomach lining and even reverse intestinal metaplasia, a precancerous change. A standout study gave non‑diabetic patients with Hp‑negative intestinal metaplasia 500 mg of metformin daily for six months. More than 48 % saw their metaplasia reverse, compared with 31 % on folic acid, and the effect jumped to 74 % in the most severe cases. Celecoxib, a COX‑2 inhibitor, showed about a 50 % reversal rate in a separate trial, though heart‑risk screening is essential. A triple combo of folic acid, vitamin B12 and teprenone reduced ten‑year gastric cancer risk to 0.5 % and improved atrophy in 40‑50 % of patients within 3‑6 months, sometimes erasing metaplasia entirely. Western drugs like rebamipide (45‑63 % reversal when paired with a PPI) and lamb gastric extract‑B12 (30‑38 % reversal) remain useful, especially for body‑predominant atrophy. On the Chinese‑medicine front, the Qilian Xiaopi Formula (WW‑1) completed a massive 468‑patient, double‑blind trial, confirming its ability to downgrade pathological scores. Experts stress that these therapies work best for mild‑to‑moderate AG after H. pylori eradication, require long treatment courses (12 weeks to 18 months), and must be prescribed by a gastroenterologist who considers staging, age, and other health issues. For high‑grade dysplasia, endoscopic removal, not medication, remains the standard. In short, a combination of repurposed drugs, targeted supplements, and modern Chinese formulas now offers a realistic path to halt or even reverse atrophic gastritis, shifting the focus from symptom control to true tissue healing.
Read more